Start Date
April 30, 2008
Primary Completion Date
April 30, 2009
Study Completion Date
April 30, 2010
Efalizumab
Efalizumab 1 mg/kg weekly subcutaneous self-administered injections for 48 weeks.
Ranibizumab
Ranibizumab 0.5 mg intravitreal injections monthly for three months followed by criteria-guided monthly injections through Month 11 (inclusive).
Eye Care Specialists, Kingston
Wilmer Eye Institute at the Johns Hopkins University, Baltimore
Texas Retina Associates, Arlington
University of Utah, Salt Lake City
Diego H. Calonje, M.D., P.C., Tucson
Retina Macula Institute, Torrance
Sharp Rees-Stealy Medical Group, San Diego
Retina Associates of Maine, Bangor
Retina Center of Maine, South Portland
Ophthalmic Consultants of Boston, Boston
Collaborators (2)
Juvenile Diabetes Research Foundation
OTHER
Genentech, Inc.
INDUSTRY
Johns Hopkins University
OTHER